Alexander Davis

Alexander Davis serves as a Clinical Lecturer at the Northern Clinical School within the Faculty of Medicine and Health at the University of Sydney, where he integrates clinical practice with translational oncology research. His work focuses on molecular biomarkers and treatment outcomes in lung cancer, contributing to both academic literature and patient care through active publication and clinical collaboration.

Dr Davis completed his doctoral thesis titled "The Role of Co Mutations in clinical and pre clinical outcomes in KRAS mutant non small cell lung cancer" under the supervision of Professors Nick Pavlakis, Wendy Cooper, Kate Mahon, and Steven Kao at the University of Sydney. This foundational work established his expertise in molecular oncology and clinical outcomes research.

His research spans lung cancer with concentrated emphasis on KRAS mutation subtypes (particularly G12C and G12D), PD-L1 biomarker dynamics, and immunotherapy efficacy in molecularly defined cohorts. He investigates how co-mutations influence therapeutic responses in non-small cell lung cancer (NSCLC) and explores emerging treatments for malignant pleural mesothelioma. His clinical work includes detailed analysis of immune-related adverse events such as nivolumab-induced cholangitis, demonstrating his commitment to improving safety profiles of novel therapies.

Analysis of Dr Davis's publication trajectory (2019-2025) reveals a strategic focus on real-world evidence generation within Australian oncology. His research consistently examines molecular determinants of treatment response, with particular attention to KRAS-mutant NSCLC cohorts and biomarker-driven therapeutic decision-making. The integration of clinical data with molecular profiling across multiple Australian institutions highlights his collaborative approach to advancing precision oncology.

Scientific Awards:

• No scientific awards were documented in the available information.

Dr Davis has established himself as a principal investigator in multiple clinical studies examining mutation-specific outcomes and immunotherapy complications. His thesis supervision by senior oncology academics indicates active participation in research training, though specific student mentorship details are not publicly enumerated. His work aligns with national priorities in lung cancer research, particularly through Australian multi-center collaborations examining workers' compensation cohorts and novel therapeutic approaches.

As part of the Northern Clinical School, Dr Davis collaborates with clinical teams across Northern Sydney Local Health District facilities. His research infrastructure leverages university-hospital partnerships for translational studies, though specific laboratory names or dedicated research teams are not publicly identified in available sources.